InventisBio Co., Limited (688382.SS)

InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China. Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer; Taragarestrant (D-0502), which is in phase III and II to treat estrogen receptor positive/human epidermal growth factor receptor 2-breast cancer. The company also develops D—2570, which is in phase III, II, and I clinical trials, as well as preclinical trials to treat autoimmune disease; and Darbinurad (D-0120), which is in phase II clinical trial to treat gout. In addition, it is developing YF087 which is in preclinical trial to treat MSI-high solid tumors; YF550 which is in preclinical trial to treat chromosome instability solid tumors; and YF057 which is in preclinical trial to treat atopic dermatitis and asthma. InventisBio Co., Limited was founded in 2013 and is based in Shanghai, China.